Articles related to MYELOFIBROSIS
JAK Inhibitors in the Treatment of Myelofibrosis
JAK inhibitors provide a relatively tolerable drug option for controlling symptoms, reducing splenomegaly, and improving quality of life, but often at the expense of worsening cytopenias and without halting disease progression or preventing leukemic transformation. In this article, the authors review FDA–approved JAK inhibitors as well as those in late-phase clinical trials, and provide a schema for choosing among the available options for patients with MF.
Hematology/Oncology August 8th 2022
How Early Intervention Impacts Long-Term Survival in Myelofibrosis
Srdan Verstovsek, MD, PhD of MD Anderson Cancer Center, is interviewed for answers to the questions of when to start treatment in a patient with myelofibrosis, an update on current treatment options, considerations for selecting treatment, dose optimization, sequencing of therapy, and more.
Hematology/Oncology June 21st 2022